期刊
THROMBOSIS AND HAEMOSTASIS
卷 106, 期 5, 页码 868-876出版社
GEORG THIEME VERLAG KG
DOI: 10.1160/TH11-05-0358
关键词
Clinical trials; oral anticoagulants; heart; prevention
Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF).They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据